Dynamics of rheological and biochemical blood parameters of patients with an intermediate stage of the dry form of age-related macular degeneration before and after serum cascade filtration

Abstract

BACKGROUND: One of the socially significant ophthalmic diseases is the dry form of the age-related macular degeneration, the key feature of which consists in a slowly progressing damage to the pigment epithelium and the formation of drusen. However, the basic mechanisms of pathogenesis are still not completely clear nowadays.

AIM: The aim is, using the data of OCT, OCT-angiography and visometry, to study the dynamics of structural and functional parameters of the macular area, as well as the dynamics of rheological and biochemical blood parameters in patients with an intermediate stage of the dry form of age-related macular degeneration before and after the use of serum cascade filtration.

MATERIALS AND METHODS: The study included 63 patients (94 eyes) with an intermediate stage of the dry form of age-related macular degeneration. Patients were randomly separated into two groups. The first (main) group consisted of 34 patients (52 eyes), in whom serum cascade filtration was performed; the second group (control) group included 29 patients (42 eyes) who did not receive any specific treatment. In patients of the main group, before and after the serum cascade filtration course (1 month after the start of follow-up), in 6 and 12 months, in addition to standard ophthalmological examination, as an indicator of the efficacy of performed serum cascade filtration, the ultrasound triplex scanning in color Doppler mapping mode with an assessment of blood flow velocity in the posterior short ciliary arteries, Fourier IR spectroscopy, and the testing of the serum and blood viscosity were performed. Patients in the control group also underwent a similar examination at 1, 6, 12 months after the start of follow-up.

RESULTS: According to optical coherence tomography, optical coherence tomography-angiography and visometry data, we found a positive dynamics of structural and functional parameters of the macular retina and an improvement in blood rheological parameters with an increase in microcirculation indices against the background of the serum cascade filtration use in treatment of patients with an intermediate stage of the dry form of age-related macular degeneration. At the same time, a statistically significant difference between the two groups begins at 1 month and persists for 12 months of follow-up, being an evidence of the stabilization of the pathological process.

CONCLUSIONS: This study showed that after the serum cascade filtration in patients with an intermediate stage of the dry form of age-related macular degeneration, against the background of an improvement in blood rheological and biochemical parameters, there was an improvement in structural and functional parameters of the macular area, which consisted in a decrease of the volume of the drusenoid retinal pigment epithelium detachment and in a visual acuity amelioration.

Keywords

age-related macular degeneration / treatment of the dry form of age-related macular degeneration / serum cascade filtration

References

[1] Izmaylov AS. Treatment of a “dry” form of age-related macular degeneration. RMJ. Clinical Ophthalmology. 2017;1:56-60. (In Russ.) EDN: YTFDXF doi: 10.21689/2311-7729-2017-17-1-56-60

[2] Измайлов А.С. Лечение «сухой» формы возрастной макулярной дегенерации // РМЖ Клиническая офтальмология. 2017. Т. 1. С. 56–60. EDN: YTFDXF doi: 10.21689/2311-7729-2017-17-1-56-60

[3] Donders FC. Contributions to the pathological anatomy of the eye. Contributions to the pathological anatomy of the eye. Archiv für Ophthalmologie. 1855;1:106–118. (In German.)

[4] Donders F.C. Beiträge zur pathologischen Anatomie des Auges. Contributions to the pathologic anatomy of the eye // Archiv für Ophthalmologie. 1855. Vol. 1. P. 106–118.

[5] Hutchinson J. Symmetrical central choroido-retinal disease occurring in senile persons // The Royal London Ophthalmic Hospital Records and Journal of Ophthalmic Medicine And Surgery. 1874. P. 231–244.

[6] Haab O. Erkrankungen der Macula lutea. Disaes of the macula lutea. Centralblat für praktische Augenheilkunde. 1885. P. 384–391. (In German.)

[7] Haab O. Erkrankungen der Macula lutea. Disaes of the macula lutea. Centralblat für praktische Augenheilkunde. 1885. P. 384–391.

[8] Haab O. Atlas und Grundriss der Ophthalmoskopie und ophthalmoskopischen Diagnostik. Atlas and outline of ophthalmoscopy and ophthalmoskopic diagnostics. Lehmann: München, 1908. P. 2. (In German.)

[9] Haab O. Atlas und Grundriss der Ophthalmoskopie und ophthalmoskopischen Diagnostik. Atlas and outline of ophthalmoscopy and ophthalmoskopic diagnostics. Lehmann: München, 1908. P. 2.

[10] Gass JD. Drusen and disciform macular detachment and degeneration. Arch Ophthalmol. 1973;90(3):206–217. doi: 10.1001/archopht.1973.01000050208006.

[11] Gass J.D. Drusen and disciform macular detachment and degeneration // Arch Ophthalmol. 1973. Vol. 90, N. 3. P. 206–217. doi: 10.1001/archopht.1973.01000050208006.

[12] Liebman ES, Shakhova EV. Blindness and disability due to pathology of the organ of vision in Russia. The Russian Annals of Ophthalmology. 2006;122(1):209–2014. (In Russ.) EDN: YTFDXF

[13] Либман Е. С., Шахова Е. В. Слепота и инвалидность вследствие патологии органа зрения в России // Вестник офтальмологии. 2006. Т. 122, № 1. С. 209–214. EDN: YTFDXF

[14] Konyaev DA, Popova EB, Titov AA, et al. The prevalence of eye diseases in the elderly population is a global problem of modernity. Health Care of the Russian Federation. 2021;65(1):62–68. (In Russ.) EDN: RCSSVB doi: 10.47470/0044-197X-2021-65-1-62-68

[15] Коняев Д.А., Попова Е.В., Титов А.А., и др. Распространённость заболеваний глаза у пожилых — глобальная проблема современности // Здравоохранение Российской Федерации. 2021. Т. 65, № 1. С. 62–68. EDN: RCSSVB doi: 10.47470/0044-197X-2021-65-1-62-68

[16] Stahl A. The diagnosis and treatment of age-related macular degeneration. Dtsch Arztebl Int. 2020;117(29–30):513–520. doi: 10.3238/arztebl.2020.0513

[17] Stahl A. The diagnosis and treatment of age-related macular degeneration // Dtsch Arztebl Int. 2020. Vol. 117, N. 29–30. P. 513–520. doi: 10.3238/arztebl.2020.0513

[18] Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106–e116. doi: 10.1016/S2214-109X(13)70145-1

[19] Wong W.L., Su X., Li X., et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis // Lancet Glob Health. 2014. Vol. 2, N. 2. P. e106–e116. doi: 10.1016/S2214-109X(13)70145-1

[20] Roh M, Laíns I, Shin HJ, et al. Microperimetry in age-related macular degeneration: association with macular morphology assessed by optical coherence tomography. Br J Ophthalmol. 2019;103(12):1769–1776. doi: 10.1136/bjophthalmol-2018-313316

[21] Roh M., Laíns I., Shin H.J., et al. Microperimetry in age-related macular degeneration: association with macular morphology assessed by optical coherence tomography // Br J Ophthalmol. 2019. Vol. 103, N. 12. P. 1769–1776. doi: 10.1136/bjophthalmol-2018-313316

[22] Johnson PT, Lewis GP, Talaga KC, et al. Drusen-associated degeneration in the retina. Invest Ophthalmol Vis Sci. 2003;44(10): 4481–4488. doi: 10.1167/iovs.03-0436

[23] Johnson P.T., Lewis G.P., Talaga K.C., et al. Drusen-associated degeneration in the retina // Invest Ophthalmol Vis Sci. 2003. Vol. 44, N. 10. P. 4481–4488. doi: 10.1167/iovs.03-0436

[24] De Jong PTVM. Elusive drusen and changing terminology of AMD. Eye (Lond). 2018;32(5):904–914. doi: 10.1038/eye.2017.298

[25] De Jong P.T.V.M. Elusive drusen and changing terminology of AMD // Eye (Lond). 2018. Vol. 32, N. 5. P. 904–914. doi: 10.1038/eye.2017.298

[26] Manuilov AS, Bardakov SN, Apchel AV, et al. The experience of using cascade plasmofiltration in combined treatment with systemic lupus erythematosus on the background of programmed hemodialysis. Bulletin of the Russian Military Medical Academy. 2018;20(2):115–119. (In Russ.) EDN: XRZEVF doi: 10.17816/brmma12278/

[27] Мануилов А.С., Бардаков С.Н., Апчел А.В., и др. Опыт применения каскадной плазмофильтрации в комбинированном лечении системной красной волчанки на фоне программного гемодиализа // Вестник Российской Военно-медицинской академии. 2018. Т. 20, № 2. С. 115–119. EDN: XRZEVF doi: 10.17816/brmma12278

[28] Chew EY, Clemons TE, Agrón E, et al.; AREDS2 Research Group. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmol. 2022;140(7): 692–698. doi: 10.1001/jamaophthalmol.2022.1640

[29] Chew E.Y., Clemons T.E., Agrón E., et al.; AREDS2 Research Group. Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28 // JAMA Ophthalmol. 2022. Vol. 140, N. 7. P. 692–698. doi: 10.1001/jamaophthalmol.2022.1640

[30] Huang Z, Deng KY, Deng YM, et al. Long-term outcomes of drusenoid pigment epithelium detachment in intermediate AMD treated with 577 nm subthreshold micropulse laser: a preliminary clinical study. Int J Ophthalmol. 2022;15(3):474–482. doi: 10.18240/ijo.2022.03.16

[31] Huang Z., Deng K.Y., Deng Y.M., et al. Long-term outcomes of drusenoid pigment epithelium detachment in intermediate AMD treated with 577 nm subthreshold micropulse laser: a preliminary clinical study // Int J Ophthalmol. 2022. Vol. 15, N. 3. P. 474–482. doi: 10.18240/ijo.2022.03.16

[32] Guymer RH, Wu Z, Hodgson LAB, et al. Laser intervention in early stages of age-related macular degeneration study group. Subthreshold nanosecond laser intervention in age-related macular degeneration: the lead randomized controlled clinical trial. Ophthalmology. 2019;126(6):829–838. doi: 10.1016/j.ophtha.2018.09.015

[33] Guymer R.H., Wu Z., Hodgson L.A.B., et al. Laser intervention in early stages of age-related macular degeneration study group. Subthreshold nanosecond laser intervention in age-related macular degeneration: the lead randomized controlled clinical trial // Ophthalmology. 2019. Vol. 126, N. 6. P. 829–838. doi: 10.1016/j.ophtha.2018.09.015

[34] Brunner R, Widder RA, Walter P, et al. Influence of membrane differential filtration on the natural course of age-related macular degeneration — a randomized trial. Retina. 2000;20:483–491. doi: 10.1097/00006982-200009000-00009

[35] Brunner R., Widder R.A., Walter P., et al. Influence of membrane differential filtration on the natural course of age-related macular degeneration — a randomized trial // Retina 2000. Vol. 20. P. 483–491. doi: 10.1097/00006982-200009000-00009

[36] Swartz M, Rabetoy G. Treatment of non-exudative agerelated macular degeneration using membrane differential filtration apheresis. Invest Ophthalmol Vis Sci. 1999;40:319.

[37] Swartz M., Rabetoy G. Treatment of non-exudative agerelated macular degeneration using membrane differential filtration apheresis // Invest Ophthalmol Vis Sci. 1999. Vol. 40. P. 319.

[38] Klingel R, Fassbender C, Heibges A, et al. Rheo Net registry analysis of rheopheresis for microcirculatory disorders with a focus on age-related macular degeneration. Ther Apher Dial. 2010;14(3): 276–286. doi: 10.1111/j.1744-9987.2010.00807.x

[39] Klingel R., Fassbender C., Heibges A., et al. Rheo Net registry analysis of rheopheresis for microcirculatory disorders with a focus on age-related macular degeneration // Ther Apher Dial. 2010. Vol. 14, N. 3. P. 276–286. doi: 10.1111/j.1744-9987.2010.00807.x

[40] Maltsev DS, Kulikov AN, Chkhablani D, et al. Optical coherence tomography in the diagnosis and treatment of central serous chorioretinopathy. Bulletin of Ophthalmology. 2018;134(6):15–24. (In Russ.) EDN: VTAFQB doi: 10.17116/oftalma201813406115

[41] Мальцев Д.С., Куликов А.Н., Чхаблани, и др. Оптическая когерентная томография в диагностике и лечении центральной серозной хориоретинопатии // Вестник офтальмологии. 2018. Т. 134, № 6. С. 15–24. EDN: VTAFQB doi: 10.17116/oftalma201813406115

RIGHTS & PERMISSIONS

Eco-Vector